Huaying Morning News | Q2 Earnings Season Kicks Off! U.S. Stocks Rose Over 2% Last Week; Hong Kong Stock Market Suspended Today Due to Typhoon 'Talim'

This week, major companies including Tesla and Netflix will release their earnings reports. On Friday, popular Chinese概念股 broadly declined—the China-focused index fell 2.17%—yet gained 6.64% for the week. On Tuesday (July 18), Bank of America, Morgan Stanley, and Charles Schwab will release earnings before the U.S. market opens; on Wednesday, ASML, Goldman Sachs, and UBS Group will report pre-market, while Tesla, Netflix, and KeyBank will report after the market closes; on Thursday, TSMC will release earnings before the U.S. market opens. Hong Kong Stock Market Suspended Due to Typhoon 'Talim' The Hang Seng Index rose 0.33% on last Friday, gaining over 1,000 points for the week. Auto parts stocks stood out: Zhejiang Shibo (01057.HK) surged over 40% for the week and more than 74% month-to-date; Nexteer Automotive (01316.HK) rose over 17% weekly and over 30% month-to-date; newly listed Yaoshi Bang (09885.HK) jumped over 36% for the week—analysts suggest it may be included in the Stock Connect program by early September. Hot weather provided a boost: Dongyue Group (00189.HK), a leading refrigerant manufacturer, rose over 23% for the week. This week, China Evergrande and Kimbee Holdings will announce earnings. Due to Typhoon 'Talim', the Hong Kong Exchanges and Clearing (HKEX) suspended trading for all Hong Kong equities—including Stock Connect—and derivatives markets for the entire day. New Listings in Hong Kong and U.S. Markets Hong Kong: 1) Xin Chuan Planning (01284.HK) had originally scheduled its listing for today but was postponed due to the typhoon-induced suspension of Hong Kong trading. Its Hong Kong public offering was oversubscribed 44.2 times. During Friday’s dark pool trading, it surged as much as 19% on some brokers’ quotes and closed up 2.17%, generating HK$100 profit per lot. 2) Zhong’an Smart Living (02271.HK) announced it will issue approximately 127 million shares at HK$1.18 per share; each board lot comprises 2,000 shares. The public offering was oversubscribed 1.84 times, with a 50% allotment rate for one board lot. Its listing is expected on July 18. U.S. Markets: 1) Among the three companies that successfully listed last Friday, Apogee Therapeutics (APGE)—a biotech firm focused on inflammatory diseases—performed best, surging over 28% intraday and closing up 24.88% at $21.23, with a market capitalization exceeding $1 billion. Nabors Energy Transition Corp. II (NETDU), a special purpose acquisition company (SPAC), closed up 1.1%. Sagimet Biosciences Inc. (SGMT), a biotech firm targeting liver disease and cancer, edged down 0.31%. 2) BioNexus Gene Lab Corp. (BGLC), a supplier of raw materials and blood testing services, is expected to list tonight. Additionally, several other companies—including ODD, SRM, WRNT, and FTEL—are expected to go public later this week. Disclaimer: This article does not constitute any investment advice nor is it tailored to the specific investment objectives, financial situation, or individual needs of any investor.

MRD Technology Makes Its Debut Overseas; IVD Companies Forge Chinese Brands!

Leveraging a technology named 'Zhengxin’an-MRD', this major Chinese enterprise specializing in tumor genetic testing and non-traditional IVD has attracted the attention of a Nasdaq-listed company—marking the first overseas commercialization of MRD (Minimal Residual Disease) technology from China and launching a global commercialization plan beginning in Southeast Asia. It is worth noting that such technology export is extremely rare within the IVD sector—and uncommon across the broader healthcare industry—signaling the rising global competitiveness of Chinese medical technology. The protagonist here is Tongshu Genomics, which recently entered into a globally strategic licensing agreement with Nasdaq-listed BioNexus Gene Lab Corp. (BGLC). Under the agreement, Tongshu Genomics has licensed its independently developed core technology—the 'Zhengxin’an-MRD' platform for monitoring tumor minimal residual disease—to BGLC and its partners. This move makes Tongshu Genomics the first domestic company to successfully commercialize MRD technology overseas, providing strong validation of the international competitiveness of homegrown Chinese innovation. Historically, China’s medical device industry has primarily exported equipment or supplied raw materials; high-value-added cases of innovative technology licensing abroad have been exceedingly scarce. Tongshu Genomics’ successful overseas deployment of its core MRD monitoring platform represents a groundbreaking 'from zero to one' milestone. Within a certain context, this demonstrates that China’s frontier innovations in precision oncology diagnostics have advanced beyond 'catching up' and 'running alongside' global leaders—entering a new phase of 'leading' and 'exporting'. Now, let us speak plainly about borderless commerce: Under the agreement, both parties will adopt a phased, systematic global rollout strategy. Phase One will focus initially on ASEAN countries—including Singapore, Malaysia, and Thailand—to secure regulatory market access, localize promotion, and implement commercial applications of the VitaGuard™ platform (built upon the 'Zhengxin’an-MRD' technology). Success in this stage will provide critical operational data, clinical feedback, and business model validation for subsequent phases. The ultimate goal is to jointly pursue regulatory approvals from the U.S. FDA and the European Medicines Agency (EMA), ultimately achieving full-scale commercialization in mainstream Western markets. This 'ASEAN-first, then target Europe and the U.S.' strategic roadmap reflects both parties’ firm confidence in the global clinical and commercial value of the 'Zhengxin’an-MRD' technology. Undoubtedly, this is recognition of technical excellence—backed by rigorous, scientifically validated clinical data. The technology employs an internationally leading second-generation 'tumor-naive' detection approach. Unlike conventional methods requiring matched tumor tissue samples from patients for comparison, the tumor-naive method achieves ultra-sensitive detection of circulating tumor DNA (ctDNA) using blood samples alone—greatly enhancing test accessibility and convenience. Behind this technological superiority lies a robust, scientifically rigorous clinical validation framework. Based on large-scale, multi-center clinical studies, the 'Zhengxin’an-MRD' technology demonstrates outstanding clinical performance, with a negative predictive value (NPV) as high as 94.4%. This means that when the test result is negative, there is an exceptionally high probability that no minimal residual disease is present—providing clinicians with a key, reliable basis for formulating subsequent treatment strategies. Moreover, related research series have already received broad recognition from top-tier international academia, with findings published in multiple high-impact international journals—cumulatively amassing over 170 points in journal impact factor.

BioNexus Gene Lab Corp (BGLC) Shareholder Structure: Major Shareholders & Institutional Holdings

Jul 26, 2026

BioNexus Gene Lab Corp reported its shareholder structure, listing major holders like Fidelion Diagnostics and ARC Group, alongside institutional holdings data through Q1 2026.

TradingKey

2026-05-12

BioNexus Gene Lab Corp (BGLC)

2026-06-18

BioNexus Gene Lab Corp (BGLC) Earnings Forecast: Future EPS & Revenue Growth Estimates

2026-06-18

BioNexus Gene Lab Corp (BGLC) Institutional Confidence

2026-06-18

BioNexus Gene Lab Corp (BGLC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

2026-06-18

BioNexus Gene Lab Corp Announces 10-to-1 Merger Stock Split